Alligator Bioscience: Interview with CEO Søren Bregenholt about OPTIMIZE-1

Research Interview



Redeye has interviewed Søren Bregenholt, CEO of Alligator Bioscience, about the positive topline results from OPTIMIZE-1, the study of mitazalimab in first-line metastatic pancreatic cancer.


Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.